This publication was written in partnership with and paid for by Pfizer Inc.
The landscape for autoimmune diseases is poised to undergo potentially revolutionary changes that are expected to substantially alter the landscape and create potential opportunity for cost savings. Several biosimilar launches in the autoimmune category are anticipated, followed by the introduction of generic Janus kinase inhibitors. These developments may provide an opportunity for substantial cost savings if payers plan accordingly in the near term.
To discuss these changes and opportunities, a multispecialty health care roundtable panel was convened, composed of a rheumatologist, a gastroenterologist, a managed care medical executive, and 2 managed care pharmacy executives. The proceedings from this conversation suggest a call to action for health plans and other payers to start preparing for potential upcoming market changes.